Granules India Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,560 Cr +20.3% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
G

Granules India

Q4 FY26Pharmaceuticals & Biotechnology

Granules India Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,471Cr
+22.9% YoY
+6% QoQ
Net profit
₹202Cr
+32.9% YoY
+34.7% QoQ
Margin
24%
+3 pp YoY
+2 pp QoQ
Price₹858
Market cap₹21.3K Cr
P/E32.7

The short version

Controlled substances and ADHD medications, including lisdexamfetamine, show strong growth potential with filings in multiple countries beyond the US (EU and ROW expected from FY '29 for finished doses, APIs earlier). Granules India aims for sustained PAT positive performance on an annual basis from FY '27, despite inherent quarter-to-quarter variations in the project-driven CDMO business.

From Granules India's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Controlled substances and ADHD medications, including lisdexamfetamine, show strong growth potential with filings in multiple countries beyond the US (EU and ROW expected from FY '29 for finished doses, APIs earlier).
  • Focus on complex product filings, especially in controlled substances and oncology, with first-to-file and NCE-1 targeted launches planned, supporting day-one market entry.
  • CDMO business, including peptides and chemicals (Ascelis), aims for sustainable profitability from FY '27, with active projects advancing to commercial supply.
  • Senn Chemicals identified as a key growth pillar, expected to contribute significantly over 3-4 years.
  • New API launches and integrated formulations continue to drive API segment growth.
  • Capex (~INR600 crores) will support broad-based expansion, including new API facility, IT, and US distribution center.

2 more points from Granules India's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Granules India said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Granules India is undertaking major capex investments including building peptide API capacity at Zurich and a brownfield manufacturing facility for intermediates in India.
  • Planning for a new India peptide API facility is underway, expected to commence approximately a year later.
  • A commercial DCDA plant in Vizag is planned with an estimated capex of around INR 200 crore, moving from pilot to commercial stage in 2 to 2.5 months.
  • FY '27 capex is expected to be broad-based (~INR 600 crore), including a new API facility, IT investments, and a U.S. distribution center/warehouse.

2 more points from Granules India's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Granules India said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Sanjay Kumar stated that they cannot share information related to the order book for the Senn project.
  • The CDMO capacity is demand-linked, with capex deployment based on customer program progress and commitments.
  • Utilization was healthy in Q4 FY'26, and new capacities coming online in the second half of the year are expected to be quickly utilized.
  • The customer base is diversified, avoiding high concentration on a few clients, thus minimizing dependency risks.

Granules India — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Granules India Q4 FY26 results — key figures

Granules India Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue1,4711,197+22.9%1,388+6%
Operating profit (EBITDA)352252+39.7%308+14.3%
Operating margin24%21%+3 pp22%+2 pp
Profit before tax262198+32.3%202+29.7%
Net profit (PAT)202152+32.9%150+34.7%
EPS (₹)8.136.27+29.7%6.19+31.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.6K Cr, net profit ₹182 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Granules India and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Granules India Q4 FY26 results?

Controlled substances and ADHD medications, including lisdexamfetamine, show strong growth potential with filings in multiple countries beyond the US (EU and ROW expected from FY '29 for finished doses, APIs earlier). Granules India aims for sustained PAT positive performance on an annual basis from FY '27, despite inherent quarter-to-quarter variations in the project-driven CDMO business.

What is Granules India share price analysis?

Granules India currently shows a neutral. The stock trades at a P/E of 32.7 with a market cap of ₹21,265 Cr. Investors should review the full earnings analysis for detailed insights.

Is Granules India planning capital expenditure?

Granules India is undertaking major capex investments including building peptide API capacity at Zurich and a brownfield manufacturing facility for intermediates in India.

Keep Granules India on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.